The New Jersey Innovation Institute’s Biopharma Division, which includes BioCentriq, its cell and gene therapy development and manufacturing center, has welcomed Beth Thompson-Webb to its advisory committee. Thompson-Webb has more than two decades of experience in life sciences with a focus on advanced therapies. She serves as general manager of global commercial cell and gene therapy at Cytiva, a global provider of technologies and services that advance and accelerate the development and manufacture of therapeutics. Thompson-Webb also serves on the advisory board at Labviva, a digital marketplace for life science products in Cambridge, Massachusetts.
NJII’s advisory committee is made up of a dozen executives from leading pharmaceutical and biotech companies, and is chaired by Dr. Joanne Beck, the chief operating officer of Boston Pharmaceuticals. Peter Marks, the director of the Food and Drug Administration’s Center for Biologics Evaluation and Research is also involved, serving as a liaison to the agency.
“Beth’s expertise in cell and gene therapy commercialization and digital transformation in the life sciences will add even greater breadth and depth to our advisory committee,” said NJII Senior Vice President and General Manager for Biopharma, Dr. Haro Hartounian. “We are so honored to have her on board.”
To learn more about NJII’s Biopharma division please visit www.njii.com/biopharma.